Abeona Therapeutics (ABEO)
(Real Time Quote from BATS)
$6.61 USD
+0.07 (1.07%)
Updated Oct 8, 2024 02:36 PM ET
NA Value
NA Growth NA Momentum NA VGMAbeona Therapeutics (ABEO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.92 | $21.00 | $7.50 | 143.43% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Abeona Therapeutics comes to $15.92. The forecasts range from a low of $7.50 to a high of $21.00. The average price target represents an increase of 143.43% from the last closing price of $6.54.
Analyst Price Targets (6 )
Broker Rating
Abeona Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
7/3/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Not Available | Strong Buy |
5/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/15/2024 | Alliance Global Partners | James Molloy | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $15.92 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.38 |
ABEO FAQs
Abeona Therapeutics Inc. (ABEO) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Abeona Therapeutics Inc. (ABEO) is $15.92. The current on short-term price targets is based on 4 reports.
The forecasts for Abeona Therapeutics Inc. (ABEO) range from a low of $7.5 to a high of $21. The average price target represents a increase of $143.43 from the last closing price of $6.54.
The current UPSIDE for Abeona Therapeutics Inc. (ABEO) is 143.43%
Based on short-term price targets offered by six analysts, the average price target for Abeona Therapeutics comes to $15.92. The forecasts range from a low of $7.50 to a high of $21.00. The average price target represents an increase of 143.43% from the last closing price of $6.54.